Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

Treatment With Aspirin After Preeclampsia: TAP Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Who May Be Eligible (Plain English)

Who May Qualify: - Postpartum individuals ≥18 years old - Preeclampsia diagnosis Who Should NOT Join This Trial: - Fetal anomaly - Multiple gestation - Pre-pregnancy hypertension - Allergy or contraindication to low-dose aspirin - Pre-pregnancy diabetes Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Postpartum individuals ≥18 years old * Preeclampsia diagnosis Exclusion Criteria: * Fetal anomaly * Multiple gestation * Pre-pregnancy hypertension * Allergy or contraindication to low-dose aspirin * Pre-pregnancy diabetes

Treatments Being Tested

DRUG

Low-dose aspirin

The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.

DRUG

Placebo

The control group will receive similar appearing placebo daily for 6 months.

Locations (1)

University of Pittsburgh Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States